Cholesterol Lowering and Ezetimibe  

Oleh:

Drazen, Jeffrey M. ; Jarcho, John A. ; Morrissey, Stephen ; Curfman, Gregory D.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 358 no. 14 (Apr. 2008), page 1507.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2008.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

In this issue of the Journal, we publish the results of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial,1 which addresses the question of whether additional lowering of low-density lipoprotein (LDL) cholesterol with ezetimibe beyond the level achieved with simvastatin beneficially affects the progression of atherosclerosis. As a surrogate clinical marker for such progression, the study used imaging of the intima–media thickness of the carotid and femoral arteries. In contrast to statins, which lower LDL cholesterol by increasing its clearance, ezetimibe selectively inhibits the absorption of cholesterol by binding to Niemann–Pick C1-like 1 (NPC1L1) protein, which is . . .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali